Search Results
Apr 07, 2026, 09:00 ET Resolve Therapeutics and Institut Pasteur Collaborate to Identify Cell-Free RNA Triggers in Autoimmunity
Damaged, modified self-RNA and endogenous retroviral RNA molecules circulating in the blood are the most proximal triggers of a self-perpetuating inflammatory cascade present in diseases such
More news about: Resolve Therapeutics, LLC
Apr 07, 2026, 08:30 ET TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an agreement with an institutional healthcare investor for
More news about: TransCode Therapeutics, Inc.
Apr 07, 2026, 08:00 ET Zymo Research and STORI Advance Early Pregnancy Detection with Cell-Free DNA Technology
challenges.Known also as The Epigenetics Company, Zymo Research offers a comprehensive range of technologies, including solutions for sample collection, DNA/RNA purification, library preparation, microbiomics, transcriptomics, epigenomics, genomics, and Next-Generation Sequencing (NGS) services.In addition
More news about: Zymo Research Corp.
Apr 06, 2026, 09:20 ET NeuroSense Granted Brazilian Patent Covering PrimeC Composition
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable
More news about: NeuroSense
Apr 06, 2026, 08:00 ET PIONEERING BRITISH BRAND, LYMA, ANNOUNCES FURTHER US EXPANSION
activation from a consumer device.Key science headlines include:45 genes activated by LYMA Laser vs. 1 gene by LED, in RNA sequencing analysis6x increase in SIRT1 — the longevity gene — expression32x increase in TXNRD1, responsible for oxidative
More news about: LYMA
Apr 02, 2026, 09:00 ET Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia's Sudair Industrial City
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Apr 01, 2026, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for April 2026
8 - Translational Imaging to Accelerate Cardiovascular Drug DevelopmentApr 14 - Fast-Tracking IVT mRNA Candidate Selection Through Smarter RNA DesignApr 15 - Accelerating GLP-1 Peptides to Market Through Integrated Formulation & Analytical DevelopmentApr 22
More news about: Xtalks
Mar 31, 2026, 16:01 ET Co-Diagnostics Reports Full Year 2025 Financial Results
diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Mar 31, 2026, 11:00 ET Alltrna Announces Approval to Initiate First-in-Human Clinical Trial of AP003, the First tRNA Therapeutic to Enter Clinical Trials
Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced approval to initiate a Phase 1
More news about: Alltrna
Mar 31, 2026, 09:20 ET NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable
More news about: NeuroSense
Mar 30, 2026, 12:34 ET Skyhawk Therapeutics Announces its Founding Scientific Advisory Board Chairman Receives the American Cancer Society's 2026 Medal of Honor
2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA targets for a series of challenging diseases, announces that the
More news about: Skyhawk Therapeutics
Mar 30, 2026, 02:23 ET EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
was the percent change from baseline in fasting triglycerides at six months compared to placebo. About olezarsen Olezarsen is an RNA-targeted medicine being evaluated for the treatment of sHTG. Olezarsen is designed to lower the body's production of apoC-III, a protein produced in
More news about: Swedish Orphan Biovitrum AB
Mar 29, 2026, 08:57 ET n6 Launches icon16™, Expanding AutoNorm™ Adaptive Amplification to Lower-Throughput NGS Workflows
emerging sequencing modalities.AutoNorm is increasingly used in workflows such as cfDNA sequencing, minimal residual disease detection, single-cell RNA sequencing, and spatial transcriptomics, where amplification bias can significantly impact downstream results. The platform is sequencer- and application-agnostic,
More news about: n6
Mar 28, 2026, 14:39 ET Das Critical Path Institute startet die Initiative „One to Millions", um die Zukunft der personalisierten Medizin weltweit neu zu gestalten
Erkrankungen ermöglichen soll. Der rasante technologische Fortschritt in Bereichen wie Antisense-Oligonukleotiden, Genom-Editierung, Gentherapien und RNA-basierten Behandlungen ermöglicht es, präzise zielgerichtete Therapien für sehr kleine Patientengruppen oder sogar einzelne Patienten zu entwickeln.
More news about: Critical Path Institute
Mar 27, 2026, 13:25 ET Critical Path Institute spouští iniciativu „Jedna k milionům" s cílem přetvořit budoucnost personalizované medicíny v globálním měřítku
individualizované stavy. Rychlý pokrok v technologiích, jako jsou protisměrné (antisense) oligonukleotidy (ASO), editace genomu, genové terapie a léčby založené na RNA, umožňuje navrhovat přesně zacílené zákroky pro velmi malé skupiny pacientů, dokonce i pro jednotlivé pacienty. Stávající regulační a úhradové rámce,
More news about: Critical Path Institute
Mar 27, 2026, 13:20 ET Critical Path Institute uruchamia inicjatywę „Od jednego do milionów", aby zmienić przyszłość medycyny spersonalizowanej w skali globalnej
zindywidualizowanych warunkach. Szybki postęp w takich technologiach jak oligonukleotydy antysensowne, edycja genomu, terapie genowe i terapie oparte na RNA sprawia, że możliwe staje się projektowanie precyzyjnie ukierunkowanych interwencji dla bardzo małych populacji pacjentów, a nawet pojedynczych osób.
More news about: Critical Path Institute
Mar 27, 2026, 13:17 ET Critical Path Institute spúšťa program „One to Millions" - zmena budúcnosti individualizovanej medicíny v globálnom meradle
vysoko individualizované ochorenia. Rýchly pokrok v technológiách, ako sú antisense oligonukleotidy, editácia genómu, génové terapie a liečby založené na RNA, umožňuje navrhovať presne cielené postupy pre veľmi malé populácie pacientov, dokonca aj pre individuálnych pacientov. Existujúce rámce pre regulácie
More news about: Critical Path Institute
Mar 26, 2026, 14:17 ET Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
therapies for highly individualized conditions. Rapid advances in technologies such as antisense oligonucleotides, genome editing, gene therapies, and RNA-based treatments are making it possible to design precisely targeted interventions for very small patient populations, even individual patients. However,
More news about: Critical Path Institute
Mar 26, 2026, 14:01 ET Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
therapies for highly individualized conditions. Rapid advances in technologies such as antisense oligonucleotides, genome editing, gene therapies, and RNA-based treatments are making it possible to design precisely targeted interventions for very small patient populations, even individual patients. However,
More news about: Critical Path Institute
Mar 26, 2026, 10:03 ET MGI Tech bringt auf der Analytica 2026 erstmals den Hochdurchsatz-Sequenzierer T7+ auf den europäischen Markt
Kunden in Europa und Afrika zur Verfügung. Auf Basis praktischer Anwendungserfahrungen lassen sich pro Lauf bis zu 112 WGS-, 80 Single-Cell-RNA-Seq- oder 1.920 RNA-Seq-Proben verarbeiten. Dies ist das erste Mal, dass das Instrument in voller Größe dem europäischen Publikum vorgestellt wird.Die T7+-Sequenzierungsplattform
More news about: MGI Tech Co., Ltd.
Mar 26, 2026, 08:00 ET Averna Therapeutics Announces Strategic Leadership Expansion
diseases. Prior to Hillstar, he served as Chief Scientific Officer at Orna Therapeutics where he led drug discovery and development of their novel circular RNA therapeutics with application across a broad range of diseases. Additionally, he previously held senior leadership roles including Global Head of Biologics
More news about: Averna Therapeutics
Mar 26, 2026, 07:45 ET Singular Genomics Launches G4X™ Spatial Research Challenge with Award of Spatial Multiomics Study up to 1,000-Samples
will fund up to a 1,000-sample service-based study to be conducted by Singular on G4X. The selected project will include up to 1,000-plex RNA, 16-plex protein, and fH&E in every sample, enabling integrated multimodal analysis at subcellular resolution across a large cohort. Runner-up
More news about: Singular Genomics
Mar 25, 2026, 08:00 ET Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Mar 25, 2026, 06:05 ET MGI Tech Brings High-Throughput T7+ Sequencer to European Market at Analytica 2026 Debut
this high-throughput sequencing platform available to customers in Europe and Africa, enabling users to process up to 112 WGS or 80 Single cell RNA-seq or 1,920 RNA-seq in one run, based on the actual operation feedback from the client. This marks the first time the full-size instrument is being shown to
More news about: MGI Tech Co., Ltd.
Mar 24, 2026, 10:47 ET Fosun Pharma Announces 2025 Annual Results
ADCs, small molecules, and cell therapy, Fosun Pharma is strategically investing in advanced fields such as radiopharmaceuticals and small interfering RNA (siRNA). The radiopharmaceutical project SRT-007 successfully initiated Phase I clinical trials, establishing a preliminary "imaging diagnosis - targeted
More news about: Fosun Pharma